Eleven IFPMA member companies are involved in the development of new antibiotics. There are currently 34 antibacterial compounds in development (19 molecules and 15 vaccines). Eight compounds are undergoing the final stages of demonstrating their efficacy, quality, and safety (phase 3 clinical trials)…

See original article:
New research-based pharmaceutical industry report provides insights on how to slow down antimicrobial resistance (AMR) and boost antibiotic R&D

Scroll to Top